CYTOMX THERAPEUTICS I

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

08 Aug 2023 15:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023

01 Aug 2023 07:00:02 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

20 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

17 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

30 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

01 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

09 May 2023 15:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023

01 May 2023 15:01:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

25 Apr 2023 15:05:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

27 Mar 2023 15:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

22 Mar 2023 18:23:33 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming March Investor Conferences

28 Feb 2023 15:05:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

26 Jan 2023 06:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference

17 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities

05 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

05 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

22 Dec 2022 16:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

20 Dec 2022 16:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

07 Dec 2022 15:30:00 By Nasdaq GlobeNewswire

CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

17 Nov 2022 06:00:00 By Nasdaq GlobeNewswire